Cancer Research · 2016 · 31 citations · 51 references
Life SciencesImmunologyOncologyInnate ImmunityNeuro-oncologyNeuroimmunologyGlioblastomaImmuno-oncology BiomarkersKiller Cell Immunoglobulin-like Receptor GeneticsNatural Killer Cell BiologyNatural Killer Cell FunctionOncogenic VirusesExome SequencingGlioblastoma PrognosisKiller Cell Immunoglobulin-like Receptor Gene PolymorphismKiller Cell Immunoglobulin-like Receptor SequencingNatural Killer Cell Receptor Nkg2dNatural Killer Cell Receptor PolymorphismsNatural Killer Cell Receptor-ligand InteractionsTumor Exome Sequencing
By affecting immunological presentation, the presence of cytomegalovirus in some glioblastomas may impact progression. In this study, we examined a hypothesized role for natural killer (NK) cells in impacting disease progression in this setting. We characterized 108 glioblastoma patients and 454 healthy controls for HLA-A,-B,-C, NK-cell KIR receptors, and CMV-specific antibodies and correlated these metrics with clinical parameters. Exome sequences from a large validation set of glioblastoma patients and control individuals were examined from in silico databases. We demonstrated that the KIR allele KIR2DS4*00101 was independently prognostic of prolonged survival. KIR2DS4*00101 displayed 100% concordance with cognate HLA-C1 ligands in glioblastoma patients, but not controls. In the context of both HLA-C1/C2 ligands for the KIR2DS4 receptor, patient survival was further extended. Notably, all patients carrying KIR2DS4*00101 alleles were CMV seropositive, but not control individuals, and exhibited increased NK-cell subpopulations, which expressed the cytotoxicity receptors CD16, NKG2D, and CD94/NKG2C. Finally, healthy controls exhibited a reduced risk for developing glioblastoma if they carried two KIR2DS4*00101 alleles, where protection was greatest among Caucasian individuals. Our findings suggest that KIR2DS4*00101 may offer a molecular biomarker to identify intrinsically milder forms of glioblastoma. Cancer Res; 76(18); 5326-36. ©2016 AACR.
51
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp, Warren Mason, Martin J. van den Bent et al. · New England Journal of Medicine · 2005 · 21.6K citations · Full text
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi, Steven O’Day, David F. McDermott et al. · New England Journal of Medicine · 2010 · 15.2K citations · Full text
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok, Harriet M. Kluger, Margaret K. Callahan et al. · New England Journal of Medicine · 2013 · 4.2K citations · Full text
Medicine, Oncology, Pharmacology +17
Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy
Klas Kärre, Hans Ljunggren, Gerald E. Piontek et al. · Nature · 1986 · 2.1K citations
Life Sciences, Immunology, Oncology +12